Pierre Magnan - Voyageur Pharmaceuticals Independent Director
| VM Stock | CAD 0.05 0.01 9.09% |
Director
Mr. Pierre P.G. Magnan is Independent Director of Golden Sun Capital Inc. Mr. Magnan was a Partner with the law firm of Gowling Lafleur Henderson LLP since February 2009 and head of its Calgary Corporationrationrate Finance and MA group since January 2010. Prior thereto was a Partner with Osler Hoskin Harcourt LLP since March 2006. Mr. Magnan is a Director of Mobovivo Inc., Synchronicity Energy Inc. and Deer Grove Inc. He is also the Corporationrationrate Secretary of Xtend Energy Services Inc. and a former Director of LeBoldus Capital Inc., a CPC, prior to the completion of its qualifying transaction in August 2010. Mr. Magnan was a Trustee of the Regional Authority of Greater Southern Public Francophone Education Region No. 4 from October 2007 to October 2010 since 2008.
| Age | 38 |
| Tenure | 16 years |
| Address | 4103B Center Street, Calgary, AB, Canada, T2E 2Y6 |
| Phone | 587 779 6166 |
| Web | https://voyageurpharmaceuticals.ca |
Voyageur Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.359) % which means that it has lost $0.359 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.965) %, meaning that it created substantial loss on money invested by shareholders. Voyageur Pharmaceuticals' management efficiency ratios could be used to measure how well Voyageur Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.08 in 2024. Return On Capital Employed is likely to drop to -0.08 in 2024. At this time, Voyageur Pharmaceuticals' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to climb to about 2.3 M in 2024, whereas Other Assets are likely to drop 0.86 in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Brian Tobin | Element Fleet Management | 62 | |
| Robert Coallier | Stella Jones | 58 | |
| Karen Albrechtsen | Winpak | N/A | |
| Alexander Greene | Element Fleet Management | 60 | |
| Rubin McDougal | Element Fleet Management | 62 | |
| Martti AarnioWihuri | Winpak | N/A | |
| James Manzi | Stella Jones | 69 | |
| Daniel Picotte | Stella Jones | 62 | |
| Donna Toth | ECN Capital Corp | 57 | |
| Donald Chatterley | Winpak | N/A | |
| Rocco Colella | Element Fleet Management | N/A | |
| Carol Goldman | ECN Capital Corp | 61 | |
| Pierre Lortie | Element Fleet Management | 68 | |
| Pierre Pomerleau | Richelieu Hardware | N/A | |
| Karen Laflamme | Stella Jones | 56 | |
| Marc Poulin | Richelieu Hardware | 52 | |
| Alan Martyszenko | Winpak | N/A | |
| Andrew Clarke | Element Fleet Management | 48 | |
| Richard Venn | Element Fleet Management | 65 | |
| Jean Douville | Richelieu Hardware | 70 | |
| Paul Stoyan | ECN Capital Corp | 60 | |
Management Performance
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.36 |
Voyageur Pharmaceuticals Leadership Team
Elected by the shareholders, the Voyageur Pharmaceuticals' board of directors comprises two types of representatives: Voyageur Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Voyageur. The board's role is to monitor Voyageur Pharmaceuticals' management team and ensure that shareholders' interests are well served. Voyageur Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Voyageur Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Merle Olson, Director | ||
| Randy Henkle, Director | ||
| Brent Willis, Chief Executive Officer, Director | ||
| Albert Deslauriers, Chief Officer | ||
| Evatt Merchant, Independent Director | ||
| Brent BscEng, CEO President | ||
| Joseph Campo, Independent Director | ||
| Christopher Wolfenberg, President CEO, Director | ||
| Greg Lindsey, Chief Financial Officer, Corporate Secretary, Director | ||
| Bradley PEng, COO Founder | ||
| Pierre Magnan, Independent Director | ||
| Trent Abraham, Director |
Voyageur Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Voyageur Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 6.97 M | ||||
| Shares Outstanding | 138.81 M | ||||
| Shares Owned By Insiders | 10.21 % | ||||
| Number Of Shares Shorted | 9.54 K | ||||
| Price To Book | 6.28 X | ||||
| EBITDA | (1.34 M) | ||||
| Net Income | (1.4 M) | ||||
| Cash And Equivalents | 27.59 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Voyageur Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Voyageur Pharmaceuticals' short interest history, or implied volatility extrapolated from Voyageur Pharmaceuticals options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyageur Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Voyageur Stock analysis
When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |